The role of NLRP3 inflammasome in the pathogenesis of rheumatic disease

References

• Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407–420.
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165(4):792–800.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10(2):128.
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. IJMS. 2019;20(13):3328.
   Google Scholar
• Chauhan D, Vande Walle L, Lamkanfi M. Therapeutic modulation of inflammasome pathways. Immunol Rev. 2020;297(1):123–138.
   PubMed Web of Science ®Google Scholar
• Zahid A, Li B, Kombe AJK, et al. Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol. 2019;10(2538):2538.
   PubMedGoogle Scholar
• Jiang H, Gong T, Zhou R. The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases. Adv Immunol. 2020;145:55–93.
   PubMed Web of Science ®Google Scholar
• Liu E, Perl A. Pathogenesis and treatment of autoimmune rheumatic diseases. Curr Opin Rheumatol. 2019;31(3):307–315.
   PubMed Web of Science ®Google Scholar
• Selmi C, Generali E, Massarotti M, et al. New treatments for inflammatory rheumatic disease. Immunol Res. 2014;60(2-3):277–288.
   PubMed Web of Science ®Google Scholar
• Ermann J, Rao DA, Teslovich NC, et al. Immune cell profiling to guide therapeutic decisions in rheumatic diseases. Nat Rev Rheumatol. 2015;11(9):541–551.
   PubMed Web of Science ®Google Scholar
• Place DE, Kanneganti TD. Recent advances in inflammasome biology. Curr Opin Immunol. 2018;50:32–38.
   PubMed Web of Science ®Google Scholar
• Evavold CL, Kagan JC. Inflammasomes: Threat-Assessment organelles of the innate immune system. Immunity. 2019;51(4):609–624.
   PubMed Web of Science ®Google Scholar
• Proell M, Gerlic M, Mace PD, et al. The CARD plays a critical role in ASC foci formation and inflammasome signalling. Biochem J. 2013;449(3):613–621.
   PubMedGoogle Scholar
• Lechtenberg BC, Mace PD, Riedl SJ. Structural mechanisms in NLR inflammasome signaling. Curr Opin Struct Biol. 2014;29:17–25.
   PubMed Web of Science ®Google Scholar
• Vanaja SK, Rathinam VA, Fitzgerald KA. Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol. 2015;25(5):308–315.
   PubMed Web of Science ®Google Scholar
• Franchi L, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13(4):325–332.
   PubMed Web of Science ®Google Scholar
• Liu D, Zeng X, Li X, et al. Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators. Biochem Pharmacol. 2020;175:113863.
   PubMed Web of Science ®Google Scholar
• Jin C, Flavell RA. Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol. 2010;30(5):628–631.
   PubMed Web of Science ®Google Scholar
• He Y, Hara H, Núñez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012–1021.
   PubMed Web of Science ®Google Scholar
• Zito G, Buscetta M, Cimino M, et al. Cellular models and assays to study NLRP3 inflammasome biology. IJMS. 2020;21(12):4294.
   Google Scholar
• Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev. 2015;265(1):35–52.
   PubMed Web of Science ®Google Scholar
• Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015;265(1):6–21.
   PubMed Web of Science ®Google Scholar
• Horvath GL, Schrum JE, De Nardo CM, et al. Intracellular sensing of microbes and danger signals by the inflammasomes. Immunol Rev. 2011;243(1):119–135.
   PubMed Web of Science ®Google Scholar
• Yang J, Liu Z, Xiao TS. Post-translational regulation of inflammasomes. Cell Mol Immunol. 2017;14(1):65–79.
   PubMed Web of Science ®Google Scholar
• Shim DW, Lee KH. Posttranslational regulation of the NLR family pyrin Domain-Containing 3 inflammasome. Front Immunol. 2018;9:1054.
   PubMed Web of Science ®Google Scholar
• Moretti J, Blander JM. Increasing complexity of NLRP3 inflammasome regulation. J Leukoc Biol. 2021;109(3):561–571.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Vande Walle L, Kanneganti TD. Deregulated inflammasome signaling in disease. Immunol Rev. 2011;243(1):163–173.
   PubMedGoogle Scholar
• Heymann MC, Rösen-Wolff A. Contribution of the inflammasomes to autoinflammatory diseases and recent mouse models as research tools. Clin Immunol. 2013;147(3):175–184.
   PubMed Web of Science ®Google Scholar
• Fusco R, Siracusa R, Genovese T, et al. Focus on the role of NLRP3 inflammasome in diseases. IJMS. 2020;21(12):4223.
   Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Guo C, Fu R, Wang S, et al. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin Exp Immunol. 2018;194(2):231–243.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zheng Y, Li H. NLRP3 inflammasome plays an important role in the pathogenesis of Collagen-Induced arthritis. Mediators Inflamm. 2016;2016:9656270.
   PubMed Web of Science ®Google Scholar
• Choulaki C, Papadaki G, Repa A, et al. Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):257.
   PubMedGoogle Scholar
• Zhao C, Gu Y, Zeng X, et al. NLRP3 inflammasome regulates Th17 differentiation in rheumatoid arthritis. Clin Immunol. 2018;197:154–160.
   PubMed Web of Science ®Google Scholar
• Ben Hamad M, Cornelis F, Marzouk S, et al. Association study of CARD8 (p.C10X) and NLRP3 (p.Q705K) variants with rheumatoid arthritis in french and tunisian populations. Int J Immunogenet. 2012;39(2):131–136.
   PubMed Web of Science ®Google Scholar
• Yang Z, Cao J, Yang Q, et al. NLRP3 p.Q705K and CARD8 p.C10X single nucleotide polymorphisms are not associated with susceptibility to rheumatoid arthritis: a Meta-analysis. Int J Rheum Dis. 2017;20(10):1481–1491.
   PubMed Web of Science ®Google Scholar
• Jenko B, Praprotnik S, Tomšic M, et al. NLRP3 and CARD8 polymorphisms influence higher disease activity in rheumatoid arthritis. J Med Biochem. 2016;35(3):319–323.
   PubMed Web of Science ®Google Scholar
• Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332–2343.
   PubMed Web of Science ®Google Scholar
• Ma ZZ, Sun HS, Lv JC, et al. Expression and clinical significance of the NEK7-NLRP3 inflammasome signaling pathway in patients with systemic lupus erythematosus. J Inflamm (Lond). 2018;15:16.
   PubMed Web of Science ®Google Scholar
• Yang Q, Yu C, Yang Z, et al. Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus. J Rheumatol. 2014;41(3):444–452.
   PubMed Web of Science ®Google Scholar
• Lech M, Lorenz G, Kulkarni OP, et al. NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-β receptor signalling. Ann Rheum Dis. 2015;74(12):2224–2235.
   PubMed Web of Science ®Google Scholar
• Lu A, Li H, Niu J, et al. Hyperactivation of the NLRP3 inflammasome in myeloid cells leads to severe organ damage in experimental lupus. J Immunol. 2017;198(3):1119–1129.
   PubMed Web of Science ®Google Scholar
• Su Z, Niu Q, Huang Z, et al. Association of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 polymorphisms with systemic lupus erythematosus disease activity and biomarker levels: a case-control study in chinese population. Medicine. 2020;99(35):e21888.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC. Association between functional NLRP3 polymorphisms and susceptibility to autoimmune and inflammatory diseases: a Meta-analysis. Lupus. 2016;25(14):1558–1566.
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–1390.
   PubMed Web of Science ®Google Scholar
• Kim SK, Cho YJ, Choe JY. NLRP3 inflammasomes and NLRP3 inflammasome-derived proinflammatory cytokines in peripheral blood mononuclear cells of patients with ankylosing spondylitis. Clin Chim Acta. 2018;486:269–274.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chen H, Wu G, et al. The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept. J Clin Lab Anal. 2017;31(6):e22138.
   PubMed Web of Science ®Google Scholar
• Ambrus JL. Jr. Sjogren's syndrome: New paradigms and areas for future research. Clin Immunol. 2017;182:1–3.
   PubMed Web of Science ®Google Scholar
• Kim SK, Choe JY, Lee GH. Enhanced expression of NLRP3 inflammasome-related inflammation in peripheral blood mononuclear cells in sjögren's syndrome. Clin Chim Acta. 2017;474:147–154.
   PubMed Web of Science ®Google Scholar
• Baldini C, Rossi C, Ferro F, et al. The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary sjögren's syndrome. J Intern Med. 2013;274(5):480–489.
   PubMed Web of Science ®Google Scholar
• Vakrakou AG, Boiu S, Ziakas PD, et al. Systemic activation of NLRP3 inflammasome in patients with severe primary sjögren's syndrome fueled by inflammagenic DNA accumulations. J Autoimmun. 2018; 91:23–33.
   PubMed Web of Science ®Google Scholar
• Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638–656.
   PubMed Web of Science ®Google Scholar
• Yin X, Han GC, Jiang XW, et al. Increased expression of the NOD-like receptor family, pyrin domain containing 3 inflammasome in dermatomyositis and polymyositis is a potential contributor to their pathogenesis. Chin Med J. 2016;129(9):1047–1052.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–2052.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Szamosi S, Kovács GE, et al. The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. Arch Biochem Biophys. 2019;670:82–93.
   PubMed Web of Science ®Google Scholar
• Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39–49.
   PubMedGoogle Scholar
• Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 2007;56(10):3183–3188.
   PubMed Web of Science ®Google Scholar
• Zhang YZ, Sui XL, Xu YP, et al. Association between nod-like receptor protein 3 inflammasome and gouty nephropathy. Exp Ther Med. 2020;20(1):195–204.
   PubMed Web of Science ®Google Scholar
• Deng J, Lin W, Chen Y, et al. rs3806268 of NLRP3 gene polymorphism is associated with the development of primary gout. Int J Clin Exp Pathol. 2015;8(10):13747–13752.
   PubMed Web of Science ®Google Scholar
• Zhang QB, Qing YF, He YL, et al. Association of NLRP3 polymorphisms with susceptibility to primary gouty arthritis in a chinese han population. Clin Rheumatol. 2018;37(1):235–244.
   PubMed Web of Science ®Google Scholar
• Glyn-Jones S, Palmer AJ, Agricola R, et al. Osteoarthritis. Lancet. 2015;386(9991):376–387.
   PubMed Web of Science ®Google Scholar
• Xu G, Wang J, Ma L, et al. Local intra-articular injection of rapamycin inhibits NLRP3 activity and prevents osteoarthritis in mouse DMM models. Autoimmunity. 2019;52(4):168–175.
   PubMed Web of Science ®Google Scholar
• Zhao LR, Xing RL, Wang PM, et al. NLRP1 and NLRP3 inflammasomes mediate LPS/ATP-induced pyroptosis in knee osteoarthritis. Mol Med Rep. 2018;17(4):5463–5469.
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699.
   PubMed Web of Science ®Google Scholar
• Martínez-Godínez MA, Cruz-Domínguez MP, Jara LJ, et al. Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients. Isr Med Assoc J. 2015;17(1):5–10.
   PubMed Web of Science ®Google Scholar
• Artlett CM, Sassi-Gaha S, Rieger JL, et al. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum. 2011;63(11):3563–3574.
   PubMedGoogle Scholar
• Coll RC, Hill JR, Day CJ, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol. 2019;15(6):556–559.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin Z, Chen D, et al. CY-09 attenuates the progression of osteoarthritis via inhibiting NLRP3 inflammasome-mediated pyroptosis. Biochem Biophys Res Commun. 2021;553:119–125.
   PubMed Web of Science ®Google Scholar
• Yang G, Lee HE, Moon SJ, et al. Direct binding to NLRP3 pyrin domain as a novel strategy to prevent NLRP3-Driven inflammation and gouty arthritis. Arthritis Rheumatol. 2020;72(7):1192–1202.
   PubMed Web of Science ®Google Scholar
• Huang Y, Jiang H, Chen Y, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018;10(4):e8689.
   PubMed Web of Science ®Google Scholar
• Marchetti C, Swartzwelter B, Koenders MI, et al. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther. 2018;20(1):169.
   PubMed Web of Science ®Google Scholar
• He H, Jiang H, Chen Y, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9(1):2550.
   PubMedGoogle Scholar
• Lee HE, Yang G, Kim ND, et al. Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout. Sci Rep. 2016;6:38622.
   PubMed Web of Science ®Google Scholar
• Lin Y, Luo T, Weng A, et al. Gallic acid alleviates gouty arthritis by inhibiting NLRP3 inflammasome activation and pyroptosis through enhancing Nrf2 signaling. Front Immunol. 2020;11(580593):580593.
   PubMedGoogle Scholar
• Rudolphi K, Gerwin N, Verzijl N, et al. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003;11(10):738–746.
   PubMed Web of Science ®Google Scholar
• Wannamaker W, Davies R, Namchuk M, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321(2):509–516.
   PubMed Web of Science ®Google Scholar
• Choi SI, Brahn E. Rheumatoid arthritis therapy: advances from bench to bedside. Autoimmunity. 2010;43(7):478–492.
   PubMed Web of Science ®Google Scholar
• Scott IC, Ibrahim F, Simpson G, et al. A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(1):88–93.
   PubMed Web of Science ®Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36(6):1118–1125.
   PubMed Web of Science ®Google Scholar
• Waugh J, Perry CM. Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs. 2005;19(3):189–202.
   PubMed Web of Science ®Google Scholar
• Saag KG, Khanna PP, Keenan RT, et al. A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol. 2021;73(8):1533–1542.
   PubMed Web of Science ®Google Scholar
• Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis. 2004;63(9):1041–1045.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54(12):2134–2144.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469–484.
   PubMed Web of Science ®Google Scholar
• Geyer M, Müller-Ladner U. Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol. 2010;22(3):246–251.
   PubMed Web of Science ®Google Scholar